HONG KONG – An artificial compound derived from vitamin A, acyclic retinoid (ACR), has been shown to selectively target cancer stem cells (CSCs) and reduce the post-therapeutic recurrence of hepatocellular carcinoma (HCC) in a new study and is currently in phase III trials for that indication in Asia.
HONG KONG – An artificial compound derived from vitamin A, acyclic retinoid (ACR), has been shown to selectively target cancer stem cells (CSCs) and reduce the post-therapeutic recurrence of hepatocellular carcinoma (HCC) in a new study and is currently in phase III trials for that indication in Asia.
HONG KONG – An antisense oligonucleotide (ASO) that induces skipping of exon 53 has been shown to have a favorable safety profile and promising pharmacokinetics in children with Duchenne muscular dystrophy (DMD) in a Japanese phase I trial. That warrants further study of the ASO in a phase II study, researchers led by Shin'ichi Takeda, director of the Department of Molecular Therapy National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP) in Tokyo, reported April 18, 2018, in Science Translational Medicine.
HONG KONG – An antisense oligonucleotide (ASO) that induces skipping of exon 53 has been shown to have a favorable safety profile and promising pharmacokinetics in children with Duchenne muscular dystrophy (DMD) in a Japanese phase I trial. That warrants further study of the ASO in a phase II study, researchers led by Shin'ichi Takeda, director of the Department of Molecular Therapy National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP) in Tokyo, reported April 18, 2018, in Science Translational Medicine.
A new U.S. study has discovered for the first time in human neurons the cause of – and a potential solution for – the primary genetic risk factor for developing Alzheimer’s disease (AD), a gene called apolipoprotein E4 (ApoE4).
HONG KONG – A neural plasticity enhancer, edonerpic maleate, could be the first clinically effective compound for accelerating rehabilitation after brain damage, potentially revolutionizing the future management of stroke patients, according to the results of a new Japanese study reported in the April 6, 2018, edition of Science.
